Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults

Annals of Internal Medicine

Volumn 161, Issue 8, 2014, Pages JC9-

  Boucher, H W ^a   Zervou, Fainareti N ^b   Zacharioudakis, Ioannis M ^b   Mylonakis, Eleftherios ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; LINEZOLID; PLACEBO; VANCOMYCIN; ANTIINFECTIVE AGENT; TEICOPLANIN;

ABSCESS; ADULT; ANTIBIOTIC THERAPY; BACTERIAL SKIN DISEASE; CELLULITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHEMA; HOSPITAL PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; NOTE; OUTPATIENT; PALPATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWELLING; TREATMENT RESPONSE; WOUND INFECTION; ANALOGS AND DERIVATIVES; FEMALE; MALE; SKIN DISEASES, BACTERIAL;

ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; SKIN DISEASES, BACTERIAL; TEICOPLANIN; VANCOMYCIN;

EID: 84924930459     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-161-8-201410210-02009     Document Type: Note

References (2)

1. Jauregui LE, Babazadeh S, Seltzer E, et al. Clin Infect Dis. 2005;41: 1407-15.
2. US Food and Drug Administration. October 2013. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071185.pdf. (accessed 27 Aug 2014)